Corteva's First Stand-Alone Quarter: A Brazil Problem It Built Itself
Guidance cut 15% on channel inventory, not weather — and management finally stopped defending the inherited cost base
CTVA · Earnings Call · 2026-11-12
The two-speed quarter
Corteva's debut as a stand-alone crop protection company was supposed to be a proof point. Instead it was a stress test. Third-quarter net sales came in at $1.6 billion, down 9% on both a reported and organic basis; operating EBITDA fell 17% to $222 million and margin compressed 140 basis points to 14%. Year to date the story still looked respectable — sales of $5.4 billion, down 1%, EBITDA of $943 million essentially flat with margins up 30 basis points despite roughly $230 million of pricing headwinds — which is precisely why the guide cut stings. The company had told investors at its September Investor Day to expect about $1.3 billion of 2026 stand-alone EBITDA; it now says $1.1–1.125 billion, implying a fourth quarter at roughly half of 2025 levels. The split was geographic and brutal. North America sales rose 7% on 19% volume growth, EMEA grew 12% (14% organic), Asia Pacific grew 3%. Latin America fell 31% organically. CFO Jeff Rudolph was blunt: “when you think about the change in our guide for the full year, it is 100% Brazil driven” — Jeffrey Rudolph, Chief Financial Officer · 2026-11-12. Half the $200 million reduction came from reduced volumes tied to channel inventory; the other half from broader market weakness including further price erosion. The largest single drag in the quarter was a roughly $120 million price headwind, about 90% of which came from two places — U.S. acetochlor at about $60 million, and generic pressure on a handful of molecules in Brazil.An overhang of its own making
Here is where the story stops being about weather. Luke Kissam did not hide behind El Niño: “We did not anticipate the magnitude nor the speed of the deterioration we have experienced in Brazil and part of that was more specific to Corteva” — Luther Kissam, Chief Executive Officer · 2026-11-12. The specificity is inventory. Too much of what Corteva sold into the Brazilian channel in the 2025 season never reached the farm gate, so the company entered this year carrying roughly $250 million of extra revenue in the channel — an elevated channel inventory position that turned a soft market into a collapse when distributors moved to just-in-time ordering. Sellout in Brazil is down roughly 12% year to date, the equivalent of about $1 billion of market, and Kissam conceded the obvious escape routes were bad business: extending credit to distributors already past due, or pushing product into North America and Europe to make the Brazilian problem a global one. That is the right call operationally and the wrong call for the near-term print. It also contrasts with the tone of three months ago, when the seed business was describing Brazilian order books as “ahead of the market” — Judd O'Connor, Executive Vice President, Seed Business Unit · 2026-07-31. In May, the framing was explicit: “we do not think that the high single digit pricing pressure is the new normal in Brazil” — Charles Victor Magro, Chief Executive Officer · 2026-07-31. Back in August 2025, Crop Protection chief Robert King had already flagged that “Brazil is probably the area where we have the most concern” — Robert King, Executive (likely EVP, Crop Protection) · 2025-08-07. The concern was real for four quarters; the quantification arrived today. Management now expects inventory levels to normalize by the end of the Brazilian growing season, with a full-year EBITDA hit of roughly $100 million attributable to the overhang alone.El Niño is shared; acetochlor is not
Separating idiosyncratic from sector matters here, and the global tape helps. el niño was a top-five market keyword in the 20262 quarter and shows up across this reporting cycle's agricultural names — salmon farmer AUSS.OL citing low harvest volumes, DOLE flagging the effect on bananas, Credicorp building El Niño provisions, Adecoagro referencing a "super El Niño," AVD pointing to a decline in U.S. crop sales. Weather is the shared, uninteresting part of the story; it is a cost to overcome, not the cause. The interesting part is what no peer shares. Acetochlor repricing is a Corteva-specific competitive decision with a visible runway: Rudolph guided to about $40 million of headwind in Q4, tapering through Q1 2027 and becoming immaterial by Q2. Five molecules account for 80% of the Brazilian price pain. Against that, differentiated products are working — new product volumes up 20% with growth in every region, Arylex and Pyraxalt each up more than 20% and together worth about $650 million in annual revenue. That is a real differentiated product engine, and it is why the non-Brazil business grew organically in a soft market.What management stopped defending
The most consequential language on the call was not about Brazil. It was about the cost base. “As I said in September, we simply cannot afford the infrastructure we inherited” — Luther Kissam, Chief Executive Officer · 2026-11-12 — followed by a hiring freeze, tightened SG&A, R&D projects shelved for a year, and a third party brought in this month to stress-test the structure over what Kissam called four to six to eight quarters. “Everything is on the table. I don't really know how else to say it” — Luther Kissam, Chief Executive Officer · 2026-11-12, he added, running through questions about whether Corteva should formulate in different places, drop products, or sell straight through distribution rather than keep feet on the ground. That is a different posture from the "controllables" framing that carried the prior four calls, where cost management and productivity were offered as the reliable offset. They still are — productivity beat expectations again in Q3, a net $67 million benefit — but the ambition has escalated from grinding out savings to re-examining whether Corteva should own its Brazilian go-to-market at all.Analysts pushed repeatedly on whether Brazil is a market to exit or restructure; no answer was given, which is itself the answer until February. Capital allocation is the second shift. Post-spin, buybacks are the obvious use of cash, but the use of cash is constrained in Q4 by the tax representations surrounding the separation. Kissam expects repurchases to be part of 2027 deployment, with the cash position guided to about $1.5 billion at year-end from $1.8 billion at Q3. The balance sheet supports it: gross margin of 57.4%, up 2.8 points year over year, against effective net cash of $2.1 billion, down 31% year over year from a $9.8 billion peak. Repurchases have kept running through the separation: $250 million bought back in the June quarter.Let's be clear. I'm not going to do anything if we can't make money. We're not. We're in the business of making money. We're in the business of growth. We're in the business of delivering returns for our shareholders. And if we can't do something toward that goal, we're not going to do it. But I want you to have the confidence that we are leaving no stone unturned in that market and any other market.